CIK 0000906709
- Non-accelerated filer
- Smaller reporting company
NEKTAR THERAPEUTICS
Sign in to watch- Ticker
- NKTR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 943134940
- Phone
- +1 415-482-5300
- Business address
- 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
- 4 Open-market sale President & CEO sold 83,334 shares at $23.57 ($1,964,182)
- 4 Open-market sale President & CEO sold 83,333 shares at $24.20 ($2,016,659)
- 4 Open-market sale SVP Pharma Dev & Mfg Ops sold 7,583 shares at $25.00 ($189,575)
- 4 Open-market sale SVP & Chief Scientific Officer sold 43,677 shares at $24.97 ($1,090,615)
- 4 Open-market sale SVP & Chief Financial Officer sold 120,000 shares at $24.45 ($2,934,000)
- 4 Open-market sale SVP & Chief Medical Officer sold 100,000 shares at an average $24.14 ($2,413,640)
- 4 Open-market sale Director sold 5,000 shares at $21.97 ($109,850)
- 4 Open-market sale Director sold 4,000 shares at $21.86 ($87,440)
- 4 Open-market sale Director sold 6,400 shares at $21.72 ($139,008)
- 4 Grant or award Director acquired 22,500 shares (grant or award)
- 4 Grant or award Director acquired 9,000 shares (grant or award)
- 4 Grant or award Director acquired 9,000 shares (grant or award)
- 4 Grant or award Director acquired 9,000 shares (grant or award)
- 4 Grant or award Director acquired 9,000 shares (grant or award)
- 4 Grant or award Director acquired 9,000 shares (grant or award)
- 4 Grant or award Director acquired 9,000 shares (grant or award)
- 4 Grant or award Director acquired 9,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale President & CEO sold 83,333 shares at $21.54 ($1,794,993)
- 4 Open-market sale SVP & Chief Accounting Officer sold 2,648 shares at $19.32 ($51,159)
Page 20 of 49 · 970 filings